1. Home
  2. OMER vs SWBI Comparison

OMER vs SWBI Comparison

Compare OMER & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • SWBI
  • Stock Information
  • Founded
  • OMER 1994
  • SWBI 1852
  • Country
  • OMER United States
  • SWBI United States
  • Employees
  • OMER N/A
  • SWBI N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • SWBI Ordnance And Accessories
  • Sector
  • OMER Health Care
  • SWBI Industrials
  • Exchange
  • OMER Nasdaq
  • SWBI Nasdaq
  • Market Cap
  • OMER 532.0M
  • SWBI 451.0M
  • IPO Year
  • OMER 2009
  • SWBI N/A
  • Fundamental
  • Price
  • OMER $9.18
  • SWBI $10.96
  • Analyst Decision
  • OMER Buy
  • SWBI Buy
  • Analyst Count
  • OMER 4
  • SWBI 2
  • Target Price
  • OMER $22.50
  • SWBI $13.00
  • AVG Volume (30 Days)
  • OMER 422.2K
  • SWBI 381.9K
  • Earning Date
  • OMER 03-31-2025
  • SWBI 03-06-2025
  • Dividend Yield
  • OMER N/A
  • SWBI 4.75%
  • EPS Growth
  • OMER N/A
  • SWBI 23.33
  • EPS
  • OMER N/A
  • SWBI 0.79
  • Revenue
  • OMER N/A
  • SWBI $514,645,000.00
  • Revenue This Year
  • OMER N/A
  • SWBI N/A
  • Revenue Next Year
  • OMER N/A
  • SWBI $6.77
  • P/E Ratio
  • OMER N/A
  • SWBI $13.89
  • Revenue Growth
  • OMER N/A
  • SWBI 0.32
  • 52 Week Low
  • OMER $2.61
  • SWBI $9.68
  • 52 Week High
  • OMER $13.60
  • SWBI $18.05
  • Technical
  • Relative Strength Index (RSI)
  • OMER 51.19
  • SWBI 57.34
  • Support Level
  • OMER $9.06
  • SWBI $10.65
  • Resistance Level
  • OMER $9.43
  • SWBI $10.94
  • Average True Range (ATR)
  • OMER 0.52
  • SWBI 0.24
  • MACD
  • OMER 0.08
  • SWBI 0.05
  • Stochastic Oscillator
  • OMER 52.25
  • SWBI 71.00

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Share on Social Networks: